Dynegene Technologies, with international advanced DNA high-throughput technology, appeared at the 72nd American Annual Conference of Human Genetics ASHG

On October 25-29 local time, the 72nd American Society of Human Genetics (ASHG) was held in Los Angeles, USA. The American Annual Conference of Human Genetics is the world's largest conference and expo on human genetics. This annual conference attracted more than 6500 scientists from all over the world in human genetics related fields and more than 250 biotechnology companies to discuss the latest progress in human genetics research and technology.

 

Dynegene Technologies, as the first domestic company with DNA high-throughput synthesis technology, appeared in ASHG

Dynegene Technologies, with the first DNA high-throughput synthesis technology in China, appeared at the conference, attracting the attention of many participating scientists and technical peers. Shi Yongyong, the chairman of the company, and Yang Yanqing, the chief commercial officer of the company, attended the meeting and had in-depth exchanges at the booth with scientists from UCLA, NIH, University of Michigan, Children's Hospital of Philadelphia, as well as technical personnel from well-known enterprises in the industry, such as Illumina and Perkinelmer.

The high-throughput DNA synthesis technology of Dynegene Technologies will enter the US market in the future to provide overseas users with high-quality, cost-effective products and services. It will provide strong support for synthetic biology, molecular diagnostic materials, biomedical tools and other fields.

 

Dynegene Technologies

 

Ultra high throughput DNA synthesis technology by microarray

After nearly 10 years of dedicated research and development, Dynegene Technologies has overcome the technical problems in synthetic chemistry, microfluidic technology, micro nano processing and surface chemistry, and successfully developed the first high-throughput DNA in situ synthesis device based on microarray chip method in China with fully independent intellectual property rights. Combining the industry-leading 3D inkjet printing technology and semiconductor chip technology, Dynegene Technologies can simultaneously synthesize DNA oligos as long as 300 nt and as many as 1.5 million pieces, with excellent synthesis accuracy and uniformity, providing unlimited potential for NGS detection, gene synthesis, high-throughput library, and antibody drug screening.

 

Micro-column High throughput DNA Independent Synthesis Technology

At this conference, Dynegene Technologies exhibited the world's only micro-column type high-throughput DNA independent synthesis technology for the first time. The patent silicon based CPG micro-column high-throughput synthesis platform can provide cost-effective single strand independent synthesis of oligonucleotides. At present, it currently supports 6K specifications, and will support 12K, 24K and other specifications in the future. It is delivered as 1536 well plates, and the amount of nucleotides per well reaches 100pmol. It fills the global technology gap that requires both high-throughput and high-yield single DNA synthesis application scenarios, which will be an important link for Dynegene Technologies to focus on the new generation of nucleic acid synthesis layout.

 

Double stranded RNA probe technology

Based on a new generation of high-throughput DNA synthesis platform, Dynegene Technologies has developed the world's first double stranded RNA probe technology, achieving a technological breakthrough in NGS capture probe. It takes into account the capture of DNA double stranded genetic information and the thermodynamic characteristics of high flexibility and strong binding force of RNA probes, and with highly optimized capture reagents, it can maximize the detection of variation information. Relying on the high throughput DNA synthesis platform and chips with national independent intellectual property rights, we can achieve the rapid delivery of hundreds of thousands of probes within a week. Compared with the uncertain factors such as the supply chain using imported raw materials, Dynegene Technologies can provide customers with stable and reliable product delivery.

 

About Dynegene Technologies

Dynegene Technologies Co. Ltd., established in 2018, is an innovative high-tech company in a rapid development period. We have won hundreds of millions of yuan of venture capital from well-known domestic investment institutions such as Volcanic Stone Capital, Chaosheng Capital, MSA Capital, Boyu Capital, Hansen Capital and ByteDance. As the only enterprises in China that develops the technology and device for the new generation of ultra-high throughput DNA synthesis and carry out commercial production, we can provide upstream raw materials, analytical tools and technical support for emerging industries such as synthetic biology, biomedicine and molecular diagnosis. Through subversive innovation, Dynegene Technologies has successfully developed a 3D inkjet printing ultra-high flux in situ nucleic acid synthesis platform with independent intellectual property rights, achieving a breakthrough in this field in China from zero to one. The technical indicators such as the flux, accuracy and length of our nucleic acid products have reached the world's first-class level. We have won the favor and recognition of customers and partners in the field of molecular diagnostics, antibody drug screening, new biological manufacturing, nucleic acid drug development, genome de novo splicing, DNA storage, space single-cell molecular genomics research.